Vitrolife acquires further shares in A.T.S.

Vitrolife acquires further shares in A.T.S.

Vitrolife is acquiring a further 9 percent of the shares in A.T.S. Srl, the
distributor of Vitrolife's products in Italy. Vitrolife thereby owns 60 percent
of the company, with an option to acquire a further 10 percent within six
months. “We are very pleased with how A.T.S has developed over the past six
months: the development of both sales and earnings has been stronger than
planned” says Magnus Nilsson, Vitrolife's CEO.

In January 2008 Vitrolife acquired 51 percent of the shares in A.T.S. Srl, the
distributor of Vitrolife's products in Italy since 1999. The acquisition is in
line with Vitrolife's strategy to operate under its own management in key
markets and increases the opportunities for A.T.S. to be more aggressive and be
able to increase its market share in the Italian market.

In the agreement there is an option for Vitrolife to acquire a further 9 percent
of the shares within 6 months and subsequently a further 10 percent within 12
months of the original acquisition date, that is a total of 70 percent. It is
the first part of this option that has now been utilized. For the first quarter
of 2008, the acquisition positively affected the consolidated sales figure by
SEK 2.4 million, with good profitability.

The seller of the shares is Paolo Trabucchi, one of the founders and previously
the sole owner of A.T.S. 

Approximately 24,000 infertility treatments are performed in Italy per year and
the number of fertility centers amounts to approximately 300. The potential
market value for instruments and media amounts to SEK 40-50 million.



July 4, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO



Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.